Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17.
Korean drug maker Celltrion announced that it has completed enrollment in its phase 3 clinical trial of CT-P17, a proposed biosimilar adalimumab, in patients with rheumatoid arthritis (RA).
The company said that it completed enrollment for the study ahead of schedule, which will allow it to complete the trial early, with the aim of an expedited product launch.
The drug maker also noted that it has developed its biosimilar to reflect high-concentration formulations of adalimumab, distinguishing the proposed product from other biosimilar adalimumab options on the market. It is also developing the product to be free of citrates, which are used in some biosimilar adalimumab formulations and which can cause discomfort to the patient during injection.
Separately, Celltrion announced that it has been in discussions with the FDA about its proposed subcutaneous formulation of CT-P13 (Inflectra, Remsima), a biosimilar infliximab product. According to a company statement, phase 1 and phase 2 trials for the subcutaneous formulation of the product will be exempted from the product’s clinical program, and only phase 3 trials will be conducted. The company says that this streamlined plan will reduce development costs and potentially facilitate early US launch of the product.
Celltrion says that it will conduct its phase 3 program in the United States in patients with inflammatory bowel disease, which it called the major indication for the US infliximab market.
In addition to making an appealing choice for patients who are satisfied with treatment with intravenous infliximab but who prefer a subcutaneous route of administration, the new formulation of CT-P13, said Celltrion, could compete with brand-name Humira, another subcutaneously administered anti—tumor necrosis factor therapy.
Currently, the subcutaneous formulation of CT-P13 is under review by the European Medicines Agency (EMA). Celltrion expects the EMA’s Committee for Medicinal Products for Human Use to deliver an opinion on the proposed formulation in the second half of 2019.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Biosimilars Development Roundup: October 2024
October 31st 2024In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.